Aurobindo Pharma's Biosimilar Growth to Peak by 2029, CEO Says

Aurobindo Pharma is developing its biosimilars business with a definite target of realizing high growth by 2029. The company believes that this year will be an inflection point in the biosimilars strategy of the company, and this will become one of the major long-term drivers of growth.

Satakarni Makkapati, the CEO of Biologics, Vaccines, and Peptides, gave information in the Q3 FY26 earnings call, the company had plans to leverage its expanding biosimilars business with Aurobindo. He observed that this commercial traction would be turned into significant contributions by 2029; this is due to the shift of development to commercialization.

The firm already has four approved oncology biosimilar products, such as Dazublys (trastuzumab) and Bevqolva (bevacizumab), with its major markets being in the European Economic Area (EEA) and Latin America. Aurobindo is also in negotiations with strategic deals in Europe to further increase penetration in the market. In line with these attempts, the biosimilars arm of Aurobindo, CuraTeQ Biologicals, has produced a line-up of vital therapies against oncology and supportive therapies, which have gained regulatory approval in Europe.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

Besides this, Aurobindo has also been granted time to get regulatory inspection by Brazil's ANVISA, making it possible to get approvals in the Brazilian market. The company is strategically positioned to make a sustained growth as it plans to have a diversified portfolio of 15 products by 2030.

Makkapati discussed the Biopharma SHAKTI scheme by the Indian government of 10,000 crore, which was set up to stimulate the development of biologics and biosimilars. His pessimistic optimism was that local capability building in clinical development and compliance with the global standards would be major determinants of the success of these initiatives.

In FY26, Aurobindo achieved good financial performance, with revenue growth of 8.4 per cent YoY and net profits of Rs 910 crore.